Economic Evaluation of Umeclidinium/Vilanterol versus Umeclidinium or Salmeterol in Symptomatic Non-Exacerbating Patients with COPD from a UK Perspective Using the GALAXY Model
Soham Shukla,1 Dhvani Shah,2 Alan Martin,3 Nancy A Risebrough,4 Robyn Kendall,5 Claus F Vogelmeier,6 Isabelle Boucot,3 Lee Tombs,7 Leif Bjermer,8 Paul W Jones,3 Edward Kerwin,9 Chris Compton,3 François Maltais,10 David A Lipson,11,12 Afisi S Ismaila1,13 1Value Evidence and Outcomes, GSK, Collegevill...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/6ae2f1ee068e4003a1696cf3ce64229f |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:6ae2f1ee068e4003a1696cf3ce64229f |
|---|---|
| record_format |
dspace |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
copd treatment cost-effectiveness umeclidinium salmeterol umeclidinium/vilanterol Diseases of the respiratory system RC705-779 |
| spellingShingle |
copd treatment cost-effectiveness umeclidinium salmeterol umeclidinium/vilanterol Diseases of the respiratory system RC705-779 Shukla S Shah D Martin A Risebrough NA Kendall R Vogelmeier CF Boucot I Tombs L Bjermer L Jones PW Kerwin E Compton C Maltais F Lipson DA Ismaila AS Economic Evaluation of Umeclidinium/Vilanterol versus Umeclidinium or Salmeterol in Symptomatic Non-Exacerbating Patients with COPD from a UK Perspective Using the GALAXY Model |
| description |
Soham Shukla,1 Dhvani Shah,2 Alan Martin,3 Nancy A Risebrough,4 Robyn Kendall,5 Claus F Vogelmeier,6 Isabelle Boucot,3 Lee Tombs,7 Leif Bjermer,8 Paul W Jones,3 Edward Kerwin,9 Chris Compton,3 François Maltais,10 David A Lipson,11,12 Afisi S Ismaila1,13 1Value Evidence and Outcomes, GSK, Collegeville, PA, USA; 2ICON, New York, NY, USA; 3Value Evidence and Outcomes, GSK, Brentford, Middlesex, UK; 4Global Health Economics, and Outcomes Research and Epidemiology, ICON, Toronto, ON, Canada; 5Global Health Economics, and Outcomes Research and Epidemiology, ICON, Vancouver, BC, Canada; 6Department of Medicine, Pulmonary and Critical Care Medicine, University Medical Center Giessen and Marburg, Philipps-Universität Marburg, Member of the German Center for Lung Research (DZL), Marburg, Germany; 7Precise Approach Ltd, Contingent Worker on Assignment at GSK, Brentford, Middlesex, UK; 8Respiratory Medicine and Allergology, Lund University, Lund, Sweden; 9Altitude Clinical Consulting and Clinical Research Institute of Southern Oregon, Medford, OR, USA; 10Centre de Pneumologie, Institut universitaire de cardiologie et de pneumologie de Québec, Université Laval, Québec, QC, Canada; 11Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; 12Respiratory Clinical Sciences, GSK, Collegeville, PA, USA; 13Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, CanadaCorrespondence: Afisi S IsmailaValue Evidence and Outcomes, GlaxoSmithKline 1250 South Collegeville Road, Collegeville, PA, 19426-0989, USATel +1 919 315 8229Email afisi.s.ismaila@gsk.comIntroduction: Dual bronchodilators are recommended as maintenance treatment for patients with symptomatic COPD in the UK; further evidence is needed to evaluate cost-effectiveness versus monotherapy. Cost-effectiveness of umeclidinium/vilanterol versus umeclidinium and salmeterol from a UK healthcare perspective in patients without exacerbations in the previous year was assessed using post hoc EMAX trial data.Methods: The validated GALAXY model was populated with baseline characteristics and treatment effects from the non-exacerbating subgroup of the symptomatic EMAX population (COPD assessment test score ≥ 10) and 2020 UK healthcare and drug costs. Outputs included estimated exacerbation rates, costs, life-years (LYs), and quality-adjusted LYs (QALYs); incremental cost-effectiveness ratio (ICER) was calculated as incremental cost/QALY gained. The base case (probabilistic model) used a 10-year time horizon, assumed no treatment discontinuation, and discounted future costs and QALYs by 3.5% annually. Sensitivity and scenario analyses assessed robustness of model results.Results: Umeclidinium/vilanterol treatment was dominant versus umeclidinium and salmeterol, providing an additional 0.090 LYs (95% range: 0.035, 0.158) and 0.055 QALYs (− 0.059, 0.168) with total cost savings of £ 690 (£ 231, £ 1306) versus umeclidinium, and 0.174 LYs (0.076, 0.286) and 0.204 QALYs (0.079, 0.326) with savings of £ 1336 (£ 1006, £ 2032) versus salmeterol. In scenario and sensitivity analyses, umeclidinium/vilanterol was dominant versus umeclidinium except over a 5-year time horizon (more QALYs at higher total cost; ICER=£ 4/QALY gained) and at the lowest estimate of the St George’s Respiratory Questionnaire treatment effect (fewer QALYs at lower total cost; ICER=£ 12,284/QALY gained); umeclidinium/vilanterol was consistently dominant versus salmeterol. At willingness-to-pay threshold of £ 20,000/QALY, probability that umeclidinium/vilanterol was cost-effective in this non-exacerbating subgroup was 95% versus umeclidinium and 100% versus salmeterol.Conclusion: Based on model predictions from a UK perspective, symptomatic patients with COPD and no exacerbations in the prior year receiving umeclidinium/vilanterol are expected to have better outcomes at lower costs versus umeclidinium and salmeterol.Keywords: COPD treatment, cost-effectiveness, umeclidinium, salmeterol, umeclidinium/vilanterol |
| format |
article |
| author |
Shukla S Shah D Martin A Risebrough NA Kendall R Vogelmeier CF Boucot I Tombs L Bjermer L Jones PW Kerwin E Compton C Maltais F Lipson DA Ismaila AS |
| author_facet |
Shukla S Shah D Martin A Risebrough NA Kendall R Vogelmeier CF Boucot I Tombs L Bjermer L Jones PW Kerwin E Compton C Maltais F Lipson DA Ismaila AS |
| author_sort |
Shukla S |
| title |
Economic Evaluation of Umeclidinium/Vilanterol versus Umeclidinium or Salmeterol in Symptomatic Non-Exacerbating Patients with COPD from a UK Perspective Using the GALAXY Model |
| title_short |
Economic Evaluation of Umeclidinium/Vilanterol versus Umeclidinium or Salmeterol in Symptomatic Non-Exacerbating Patients with COPD from a UK Perspective Using the GALAXY Model |
| title_full |
Economic Evaluation of Umeclidinium/Vilanterol versus Umeclidinium or Salmeterol in Symptomatic Non-Exacerbating Patients with COPD from a UK Perspective Using the GALAXY Model |
| title_fullStr |
Economic Evaluation of Umeclidinium/Vilanterol versus Umeclidinium or Salmeterol in Symptomatic Non-Exacerbating Patients with COPD from a UK Perspective Using the GALAXY Model |
| title_full_unstemmed |
Economic Evaluation of Umeclidinium/Vilanterol versus Umeclidinium or Salmeterol in Symptomatic Non-Exacerbating Patients with COPD from a UK Perspective Using the GALAXY Model |
| title_sort |
economic evaluation of umeclidinium/vilanterol versus umeclidinium or salmeterol in symptomatic non-exacerbating patients with copd from a uk perspective using the galaxy model |
| publisher |
Dove Medical Press |
| publishDate |
2021 |
| url |
https://doaj.org/article/6ae2f1ee068e4003a1696cf3ce64229f |
| work_keys_str_mv |
AT shuklas economicevaluationofumeclidiniumvilanterolversusumeclidiniumorsalmeterolinsymptomaticnonexacerbatingpatientswithcopdfromaukperspectiveusingthegalaxymodel AT shahd economicevaluationofumeclidiniumvilanterolversusumeclidiniumorsalmeterolinsymptomaticnonexacerbatingpatientswithcopdfromaukperspectiveusingthegalaxymodel AT martina economicevaluationofumeclidiniumvilanterolversusumeclidiniumorsalmeterolinsymptomaticnonexacerbatingpatientswithcopdfromaukperspectiveusingthegalaxymodel AT risebroughna economicevaluationofumeclidiniumvilanterolversusumeclidiniumorsalmeterolinsymptomaticnonexacerbatingpatientswithcopdfromaukperspectiveusingthegalaxymodel AT kendallr economicevaluationofumeclidiniumvilanterolversusumeclidiniumorsalmeterolinsymptomaticnonexacerbatingpatientswithcopdfromaukperspectiveusingthegalaxymodel AT vogelmeiercf economicevaluationofumeclidiniumvilanterolversusumeclidiniumorsalmeterolinsymptomaticnonexacerbatingpatientswithcopdfromaukperspectiveusingthegalaxymodel AT boucoti economicevaluationofumeclidiniumvilanterolversusumeclidiniumorsalmeterolinsymptomaticnonexacerbatingpatientswithcopdfromaukperspectiveusingthegalaxymodel AT tombsl economicevaluationofumeclidiniumvilanterolversusumeclidiniumorsalmeterolinsymptomaticnonexacerbatingpatientswithcopdfromaukperspectiveusingthegalaxymodel AT bjermerl economicevaluationofumeclidiniumvilanterolversusumeclidiniumorsalmeterolinsymptomaticnonexacerbatingpatientswithcopdfromaukperspectiveusingthegalaxymodel AT jonespw economicevaluationofumeclidiniumvilanterolversusumeclidiniumorsalmeterolinsymptomaticnonexacerbatingpatientswithcopdfromaukperspectiveusingthegalaxymodel AT kerwine economicevaluationofumeclidiniumvilanterolversusumeclidiniumorsalmeterolinsymptomaticnonexacerbatingpatientswithcopdfromaukperspectiveusingthegalaxymodel AT comptonc economicevaluationofumeclidiniumvilanterolversusumeclidiniumorsalmeterolinsymptomaticnonexacerbatingpatientswithcopdfromaukperspectiveusingthegalaxymodel AT maltaisf economicevaluationofumeclidiniumvilanterolversusumeclidiniumorsalmeterolinsymptomaticnonexacerbatingpatientswithcopdfromaukperspectiveusingthegalaxymodel AT lipsonda economicevaluationofumeclidiniumvilanterolversusumeclidiniumorsalmeterolinsymptomaticnonexacerbatingpatientswithcopdfromaukperspectiveusingthegalaxymodel AT ismailaas economicevaluationofumeclidiniumvilanterolversusumeclidiniumorsalmeterolinsymptomaticnonexacerbatingpatientswithcopdfromaukperspectiveusingthegalaxymodel |
| _version_ |
1718428990104928256 |
| spelling |
oai:doaj.org-article:6ae2f1ee068e4003a1696cf3ce64229f2021-11-14T19:00:30ZEconomic Evaluation of Umeclidinium/Vilanterol versus Umeclidinium or Salmeterol in Symptomatic Non-Exacerbating Patients with COPD from a UK Perspective Using the GALAXY Model1178-2005https://doaj.org/article/6ae2f1ee068e4003a1696cf3ce64229f2021-11-01T00:00:00Zhttps://www.dovepress.com/economic-evaluation-of-umeclidiniumvilanterol-versus-umeclidinium-or-s-peer-reviewed-fulltext-article-COPDhttps://doaj.org/toc/1178-2005Soham Shukla,1 Dhvani Shah,2 Alan Martin,3 Nancy A Risebrough,4 Robyn Kendall,5 Claus F Vogelmeier,6 Isabelle Boucot,3 Lee Tombs,7 Leif Bjermer,8 Paul W Jones,3 Edward Kerwin,9 Chris Compton,3 François Maltais,10 David A Lipson,11,12 Afisi S Ismaila1,13 1Value Evidence and Outcomes, GSK, Collegeville, PA, USA; 2ICON, New York, NY, USA; 3Value Evidence and Outcomes, GSK, Brentford, Middlesex, UK; 4Global Health Economics, and Outcomes Research and Epidemiology, ICON, Toronto, ON, Canada; 5Global Health Economics, and Outcomes Research and Epidemiology, ICON, Vancouver, BC, Canada; 6Department of Medicine, Pulmonary and Critical Care Medicine, University Medical Center Giessen and Marburg, Philipps-Universität Marburg, Member of the German Center for Lung Research (DZL), Marburg, Germany; 7Precise Approach Ltd, Contingent Worker on Assignment at GSK, Brentford, Middlesex, UK; 8Respiratory Medicine and Allergology, Lund University, Lund, Sweden; 9Altitude Clinical Consulting and Clinical Research Institute of Southern Oregon, Medford, OR, USA; 10Centre de Pneumologie, Institut universitaire de cardiologie et de pneumologie de Québec, Université Laval, Québec, QC, Canada; 11Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; 12Respiratory Clinical Sciences, GSK, Collegeville, PA, USA; 13Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, CanadaCorrespondence: Afisi S IsmailaValue Evidence and Outcomes, GlaxoSmithKline 1250 South Collegeville Road, Collegeville, PA, 19426-0989, USATel +1 919 315 8229Email afisi.s.ismaila@gsk.comIntroduction: Dual bronchodilators are recommended as maintenance treatment for patients with symptomatic COPD in the UK; further evidence is needed to evaluate cost-effectiveness versus monotherapy. Cost-effectiveness of umeclidinium/vilanterol versus umeclidinium and salmeterol from a UK healthcare perspective in patients without exacerbations in the previous year was assessed using post hoc EMAX trial data.Methods: The validated GALAXY model was populated with baseline characteristics and treatment effects from the non-exacerbating subgroup of the symptomatic EMAX population (COPD assessment test score ≥ 10) and 2020 UK healthcare and drug costs. Outputs included estimated exacerbation rates, costs, life-years (LYs), and quality-adjusted LYs (QALYs); incremental cost-effectiveness ratio (ICER) was calculated as incremental cost/QALY gained. The base case (probabilistic model) used a 10-year time horizon, assumed no treatment discontinuation, and discounted future costs and QALYs by 3.5% annually. Sensitivity and scenario analyses assessed robustness of model results.Results: Umeclidinium/vilanterol treatment was dominant versus umeclidinium and salmeterol, providing an additional 0.090 LYs (95% range: 0.035, 0.158) and 0.055 QALYs (− 0.059, 0.168) with total cost savings of £ 690 (£ 231, £ 1306) versus umeclidinium, and 0.174 LYs (0.076, 0.286) and 0.204 QALYs (0.079, 0.326) with savings of £ 1336 (£ 1006, £ 2032) versus salmeterol. In scenario and sensitivity analyses, umeclidinium/vilanterol was dominant versus umeclidinium except over a 5-year time horizon (more QALYs at higher total cost; ICER=£ 4/QALY gained) and at the lowest estimate of the St George’s Respiratory Questionnaire treatment effect (fewer QALYs at lower total cost; ICER=£ 12,284/QALY gained); umeclidinium/vilanterol was consistently dominant versus salmeterol. At willingness-to-pay threshold of £ 20,000/QALY, probability that umeclidinium/vilanterol was cost-effective in this non-exacerbating subgroup was 95% versus umeclidinium and 100% versus salmeterol.Conclusion: Based on model predictions from a UK perspective, symptomatic patients with COPD and no exacerbations in the prior year receiving umeclidinium/vilanterol are expected to have better outcomes at lower costs versus umeclidinium and salmeterol.Keywords: COPD treatment, cost-effectiveness, umeclidinium, salmeterol, umeclidinium/vilanterolShukla SShah DMartin ARisebrough NAKendall RVogelmeier CFBoucot ITombs LBjermer LJones PWKerwin ECompton CMaltais FLipson DAIsmaila ASDove Medical Pressarticlecopd treatmentcost-effectivenessumeclidiniumsalmeterolumeclidinium/vilanterolDiseases of the respiratory systemRC705-779ENInternational Journal of COPD, Vol Volume 16, Pp 3105-3118 (2021) |